These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 6896551)

  • 1. Long-term follow-up of two chemotherapy protocols in Hodgkin's disease.
    Pavlovsky S; Morgenfeld M; Somoza N; Magnasco J; Sackmann Muriel F; Cavagnaro F; Suárez A; Barros CA; Saslavsky J; Garay G; Palau M; Besuschio SC
    Medicina (B Aires); 1981; 41 Suppl():15-21. PubMed ID: 6896551
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy in advanced and recurrent Hodgkin's disease.
    McElwain TJ; Wrigley PF; Hunter A; Crowther D; Malpas JS; Peckham MJ; Smithers DW; Fairley GH
    Natl Cancer Inst Monogr; 1973 May; 36():395-402. PubMed ID: 4744597
    [No Abstract]   [Full Text] [Related]  

  • 3. [Hodgkin's disease: treatment of clinical stages II3+A, IB, IIB, IIIA and IIIB with short chemotherapy (3 MOPP, or 3 CVPP), splenectomy and limited irradiation. Results after 4 years of a prospective protocol including 94 patients].
    Andrieu JM; Casassus P; Coscas Y; Darmont J; Goubeau C; Katz M; Jacquillat C; Tricot G; Weil M
    Bull Cancer; 1982; 69(4):321-9. PubMed ID: 6897520
    [No Abstract]   [Full Text] [Related]  

  • 4. [Treatment maintaining complete remission in Hodgkin's disease].
    Armata J
    Pol Tyg Lek; 1981 Feb; 36(8):301-4. PubMed ID: 7022410
    [No Abstract]   [Full Text] [Related]  

  • 5. Long term experience with combination chemotherapy in advanced Hodgkin's disease.
    Garrett MJ; Das S; Smith JD; Freedman LS
    Clin Oncol; 1977 Jun; 3(2):145-54. PubMed ID: 68843
    [No Abstract]   [Full Text] [Related]  

  • 6. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Southeastern Cancer Study Group trials with nitrosoureas in Hodgkin's disease.
    Durant JR; Bartolucci A; Gams RA; Dorfman RF; Velez-Garcia E
    Cancer Treat Rep; 1976 Jun; 60(6):781-7. PubMed ID: 782700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two combination chemotherapies in previously untreated non Hodgkin's lymphoma.
    Somoza N; Pavlovsky S; Suárez A; Morgenfeld M; Besuschio SC; Bezares R; Quiroga Micheo E; Lein JM; De María H
    Medicina (B Aires); 1981; 41 Suppl():35-43. PubMed ID: 7345350
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug therapy of Hodgkin's disease].
    Gallmeier WM; Bruntsch U
    Internist (Berl); 1981 May; 22(5):289-300. PubMed ID: 7019138
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term survival of patients with Hodgkin's disease. Treatment with cyclophosphamide, vinblastine, procarbazine, and prednisone.
    Gibbs GE; Peterson BA; Kennedy BJ; Vosika G; Bloomfield CD
    Arch Intern Med; 1981 Jun; 141(7):897-900. PubMed ID: 7235809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease.
    Diggs CH; Wiernik PH; Levi JA; Kvols LK
    Cancer; 1977 May; 39(5):1949-54. PubMed ID: 870162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy of Hodgkin's disease in studies by acute leukemia group B.
    Nissen NI; Stutzman L; Holland JF; Glidewell OJ
    Arch Intern Med; 1973 Mar; 131(3):396-401. PubMed ID: 4688038
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined drug treatment of Hodgkin's disease: remission induction, remission duration, and survival; an appraisal.
    DeVita VT
    Natl Cancer Inst Monogr; 1973 May; 36():373-9. PubMed ID: 4744596
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term outcome of children and adolescents treated with the COPP-ABV hybrid protocol for Hodgkin's disease: balance of risks.
    Klumb CE; Carriço MK; de Rezende LM; Byington R; Bordallo MA; Bigni RS; Apa AG; Dobbin JA
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):628-9. PubMed ID: 17662581
    [No Abstract]   [Full Text] [Related]  

  • 16. Lomustine and melphalan cannot be replaced by cyclophosphamide and etoposide without reducing efficacy in MOPPEBVCAD chemotherapy for advanced Hodgkin's disease.
    Gobbi PG; Broglia C; Bertè R; Petrilli MP; Molica S; Angrilli F; Iannitto E; Ghirardelli ML; Di Renzo N; Cavanna L; Ascari E
    Haematologica; 2000 Jul; 85(7):722-8. PubMed ID: 10897124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eastern cooperative oncology group studies.
    Lenhard RE
    Arch Intern Med; 1973 Mar; 131(3):418-20. PubMed ID: 4688039
    [No Abstract]   [Full Text] [Related]  

  • 18. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Combined chemotherapy in disseminated Hodgkin's disease].
    Armata J
    Pol Tyg Lek; 1972 Jul; 27(24):927-9. PubMed ID: 4557231
    [No Abstract]   [Full Text] [Related]  

  • 20. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
    Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
    J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.